---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-069748"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T01:01:57.126761+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CEO transition at Phathom: Steven Basta appointed, Terrie Curran resigns effective March 31, 2025

## Summary
- Steven Basta appointed CEO, President and Class I director effective April 1, 2025; Terrie Curran resigned for personal reasons.
- Basta receives $700k base salary, 70% target bonus, and initial option grant of 1,085,000 shares vesting over 4 years.
- Basta also granted 360k stock-price-hurdle PSUs and 180k revenue-based PSUs (target) under new inducement plan.
- Curran severance includes base salary through June 30, 2026, 2025 target bonus lump sum, COBRA, and accelerated vesting.
- Board adopted 2025 Employment Inducement Incentive Award Plan reserving 2,500,000 shares without stockholder approval.

## SEC filing metadata
- accession: 0001193125-25-069748
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/0001193125-25-069748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/d913876d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-069748
- JSON: https://secwatch.observer/filing/0001193125-25-069748.json
- Plain text: https://secwatch.observer/filing/0001193125-25-069748.txt

## Key facts
- Executive change
  Terrie Curran resigned as President and Chief Executive Officer at Phathom Pharmaceuticals, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/0001193125-25-069748-index.htm
- Executive change
  Steven Basta was appointed as Chief Executive Officer, President and Class I director at Phathom Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer, President and Class I director
  source text: Steven Basta was appointed as the Chief Executive Officer, President and as a Class I director of Phathom Pharmaceuticals, Inc. (the “Company”), replacing Terrie Curran who resigned as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) for personal reasons, effective March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312525069748/0001193125-25-069748-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.